Navigation Links
Pharsight Achieves $7.4 Million in Quarterly Revenue
Date:1/24/2008

ther information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2007. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.

Drug Model Explorer, DMX, Pharsight, Pharsight Knowledgebase Server, PKS, PKS Validation Suite, PKS Reporter, PKS Office Client, WinNonlin, WinNonlin AutoPilot, IVIVC Toolkit for WinNonlin, Trial Simulator and WNL Validation Suite are trademarks or registered trademarks of Pharsight Corporation.

Financial Tables Follow

PHARSIGHT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

December 31, December 31,

---------------- ----------------

2007 2006 2007 2006

------- ------- ------- -------

Revenues:

License $1,406 $1,237 $4,137 $3,977

Renewal 1,851 1,444 5,332 4,084

Maintenance 307 249 926 724

Services 3,809 3,191 10,357 9,048

------- ------- ------- -------

Total revenues 7,373 6,121 20,752 17,833

Cost of revenues 2,635 1,871 7,346 5,44
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
2. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
3. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
4. Pharsight Announces 1-For-3 Reverse Stock Split
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
7. Pharsight Hosts Fourth Annual PKS User Group Meeting
8. Pharsight Expands Strategic Consulting Services Team
9. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
10. Pharsight Achieves First License Sale for Public-Source Database
11. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/13/2014)... 12, 2014 /CNW/ - MaRS and Virgin Unite Canada, the ... have joined forces to support Canadian entrepreneurs tackling social and ... Founder was at the MaRS Centre to announce the new ... venture fund. This fund has $1 million in seed capital ... -based Mindset Social Innovation Foundation, founded by Alison ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... , RICHMOND, Va., July 31 Insmed Inc. ... that it will host a conference call on Thursday, August ... for the second quarter 2009. Insmed intends to issue ... on August 13(th). , , To participate ...
... TOKYO, July 31 R-Tech Ueno, Ltd. announced on July ... board of directors held on the day and determined the R&D ... to actively strengthen R&D in the ophthalmologic & dermatological fields that ... with external entities. , , 1. Development code ...
... , , , ... ANDS ) today announced finalization of the protocol for the ... ribavirin in hepatitis C patients. Allowance of the protocol has been ... dosing is expected to commence within the next several weeks. , ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... A component of DNA that can both stimulate ... may hold hope for treating cancer and infection, Medical ... of CpG increase inflammation, part of the body,s way ... increasing expression of the enzyme indoleamine 2,3 dioxygenase, or ...
... A new study by researchers at Princeton University,s Woodrow ... that global climate change may lead to the retreat ... States, which could create unprecedented ecological restoration opportunities across ... time, global warming may enable other invasive plants to ...
... a surprising link between brain iron levels and ... from autism to major depression., Appearing in the ... this week, the study by Randy Blakely, ... a powerful in silico approach for discovering novel ...
Cached Biology News:DNA component can stimulate and suppress the immune response 2Climate change's impact on invasive plants in Western US may create restoration opportunities 2Climate change's impact on invasive plants in Western US may create restoration opportunities 3Climate change's impact on invasive plants in Western US may create restoration opportunities 4Researchers iron out new role for serotonin 2
... Dye runs faster than Bromophenol blue,or ... gels.,Orange G dye migrates with DNA ... migration at this size,prevents the obscuring ... the front of DNA migration.,The Orange ...
... Description: 100 g ... 70 kDa YAP from Human/mouse/rat samples. ... Research Focus: ... -20C Shipping ...
Rabbit polyclonal to QKI...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
Biology Products: